Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dropbox Inc (DBX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dropbox Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Dropbox Inc trades at $29.17 (market cap $6.81B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.9× Dropbox Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DBX | |
|---|---|---|
Market Cap | $39.89B | $6.81B |
Sector | Health | Technology |
52-Week High | $491.22 | $32.17 |
52-Week Low | $278.09 | $22.06 |
Enterprise Value | $38.15B | $9.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DBX trades at $29.19, down 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported revenue of $2.52 billion in 2025 with a net income margin of 20.16%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $900 million stock repurchase program and CEO transition plans announced in May 2026.
Outlook is mixed with strong profitability and consistent earnings beats offset by negative shareholder equity and high debt levels. The consensus price target of $30 suggests modest upside, but investors face risks from leadership changes and competitive pressures in cloud storage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
